HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

gadobutrol

structure in first source
Also Known As:
Gadovist; Gd-DO3A-butriol; gadolinium-DO3A-butriol
Networked: 116 relevant articles (11 outcomes, 20 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Runge, Val M: 8 articles (01/2013 - 05/2009)
2. Attenberger, Ulrike I: 6 articles (11/2012 - 05/2009)
3. Reiser, Maximilian F: 5 articles (11/2014 - 07/2007)
4. Morelli, John N: 5 articles (11/2012 - 03/2010)
5. Kauczor, Hans-Ulrich: 5 articles (06/2010 - 02/2004)
6. Tombach, Bernd: 5 articles (03/2009 - 01/2002)
7. Kramer, Ulrich: 4 articles (11/2015 - 01/2008)
8. Loewe, Christian: 4 articles (06/2015 - 09/2003)
9. Taupitz, Matthias: 4 articles (04/2014 - 09/2003)
10. Schoenberg, Stefan O: 4 articles (11/2012 - 05/2009)

Related Diseases

1. Neoplasm Metastasis (Metastasis)
2. Body Weight (Weight, Body)
03/01/2007 - "The GFR was assessed by recording the renal clearance of gadobutrol (3.75 mL, approximately 0.05 mmol per kilogram of body weight) at navigator-gated turbo fast low-angle shot magnetic resonance (MR) imaging. "
03/01/2009 - "This study documents evidence for the noninferiority of a single i.v. bolus injection of 1.0 M gadobutrol (0.1 mmol/kg body weight) to 0.5 M gadopentetate (0.1 mmol/kg body weight) in the diagnostic assessment of liver lesions with contrast-enhanced MRI. "
09/01/2003 - "The study included 50 patients, with 25 patients (group 1) injected with 0.2 mmol Gd-GTPA/kg body weight and 25 patients (group 2) injected with 0.1 mmol gadobutrol/kg body weight. "
07/01/1994 - "In this article, the authors report on the first application of gadobutrol in humans, up to a dose of 0.5 mmol/kg. Gadobutrol was investigated after single intravenous administration in two phase-1 studies testing low (0.5 mol/L) and high concentrations (1 mol/L) in healthy, male volunteers using a double-blind, randomized, placebo-controlled study with n = 55 for the low concentration (0.04, 0.1, 0.2, 0.3, and 0.4 mmol/kg body weight), followed by n = 36 for the high concentration (0.3, 0.4, and 0.5 mmol/kg body weight). "
01/01/2016 - "Pediatric subjects (term newborns to those aged younger than 2 years) with normal renal function undergoing magnetic resonance imaging with gadobutrol (0.1 mmol/kg body weight [BW]) were prospectively enrolled in this open-label, multicenter clinical trial to evaluate PK as a primary end point. "
3. Hepatocellular Carcinoma (Hepatoma)
4. Brain Neoplasms (Brain Tumor)
5. Neoplasms (Cancer)

Related Drugs and Biologics

1. Gadolinium DTPA (Magnevist)
2. Gadolinium
3. gadobutrol
4. gadoterate meglumine
5. gadobenic acid (gadobenate dimeglumine)
6. gadolinium 1,4,7,10- tetraazacyclododecane- N,N',N'',N'''- tetraacetate
7. gadoteridol (Prohance)
8. Contrast Media
9. Adenosine
10. gadolinium ethoxybenzyl DTPA

Related Therapies and Procedures

1. Intravenous Injections
2. Injections
3. Catheters
4. Synchrotrons
5. Homologous Transplantation (Allograft)